12th Congress of the European Hematology ... - Haematologica

More documents

Recommendations

Info

12 th Congress of the European Hematology Association Callet-Bauchu, E., 0288, 0292, 0887, 0908, 0922 Calori, R., 0242 Calpe, E., 0514 Caltagirone, S., 0193, 0693 Calvo, C., 0372 Calvo, F., 0546, 0958, 1343 Calvo, J.M., 1441 Calvo-Villas, J.M., 0171, 0976, 1148 Camós, M., 0487 Campagna, M., 0184 Campagna, S., 0058 Campagnoli, M.F., 0080 Campana, D., 0191 Campanati, A., 0710 Campanelli, R., 0645 Campbell, H., 1173 Campbell, J., 1322 Campioni, D., 0336 Campo, C., 1529 Campo, E., 0487, 0706 Campo Dell’Orto, M., 0152, 0169, 0892 Campos, A.D., 0797 Campos, J., 0813 Campos, P.M., 1272 Campr, V., 1044 Can, A., 1141 Can, S., 1295 Canalli, A., 0916 Canals, C., 0369, 0425 Cançado, R., 0791 Cancela, J., 0664 Canciani, M.T., 0091 Candoni, A., 0458, 0460, 0496, 0650, 1284 Candy, J., 0731 Canepa, L., 0177, 0402, 1180 Canet, S., 1291 Cangi, M.G., 0291 Cangialosi, C., 0401, 0422 Caniglia, M., 0452, 0849 Cañizo, M.C., 0328, 0426 Cannizzaro, R., 1000 Cano, I., 0268 Canovas, A., 0305 Cantalapiedra, A., 0346 Cantero, S., 0215 Canton, J., 0577 Cantonetti, M., 0616, 1187, 1381 Cantoni, S., 0644 Canzonieri, V., 1000 Cao, Y., 0584 Capaia, M., 0517 Capello, D., 0250, 0289, 1084, 1088 Capobianco, A., 0612 Capozzi, C.L., 0790, 1157 Cappellini, M.D., 0681, 0735, 0779, 0780 Capponi, C., 0849 Cappucci, A., 0562 Capria, S.C., 0612 Capucci, M.A., 0285, 0608 Capuzzi, E., 0496, 0745, 1296 Carando, A., 0080 Caravita, T., 0254, 0401, 0422, 0883 Carbonari, M., 0139 Carbone, A., 0289 Carbonell, F., 1053 Cardarelli, L., 0612 Cardelli, P., 1007 Cardoso, A., 1114 Carella, A.M., 0049, 0177, 0325, 0508, f | haematologica/the hematology journal | 2007; 92(s1) 0663, 1133, 1196, 1301, 1302, 1511, 1538 Caresana, M., 0224, 0626 Cargill, J., 0202 Caridi, G., 0438 Cario, G., 0022, 0371, 0384 Carles, C., 1475 Carli, P.M., 1067 Carli, P., 0515 Carlotti, E., 0172, 0284 Carluccio, P., 1035, 1068, 1073, 1284 Carmona, M., 0972 Carneiro, A., 0664 Carnevale, P., 0255 Carnevale Schianca, F., 0209, 0403 Carniti, C., 0724 Carobbio, A., 1127 Carola, A., 0113 Carosi, G., 0608 Carpiuc, K.T., 0552, 0658, 1116 Carr, T., 0755 Carrai, V., 0301, 1218, 1497 Carranza, C., 0869 Carranza, S., 0845 Carrara, P., 0177 Carrara, R.C., 0797 Carrara, R.V., 0963 Carraro, S., 0278, 1352 Carrasco, A., 0307 Carrera Merino, D., 0404, 1550 Carreras, E., 0487 Carreter, E., 1148 Carrio, A., 0487 Carter, A, 0910 Cartoni, C., 0763, 0764, 1345 Carturan, S., 0044, 0156, 0198, 0199, 0636, 0665 Caruso, B., 1060 Caruso, N., 0675 Caruso, R., 0080, 0750 Carvalho, M., 1028, 0352, 0353 Casadevall, N., 0249 Casado Montero, L.F., 0268, 0668, 1201 Casado-Garcia, T.M., 0680 Casagrande, G., 0024 Casal, I., 1384 Casalou, C., 0005, 0473 Casalta, J.E., 1131 Casanova, M., 1068 Casato, M., 0139 Cascavilla, N., 0254, 0325, 0650, 1133, 1196, 1301, 1302, 1511 Casini, C., 0259, 0260 Casini, M., 0403 Casleanu, D., 1398 Cassetta, M.I., 0991 Cassinat, B., 0639 Castagna, L., 0403 Castagnetti, F., 0006, 0140, 0536, 0549, 0550, 0559, 0561, 0562, 0906 Castagnola, C., 0626, 1350 Castaigne, S., 0048, 0077, 0397, 0467, 0474, 0547, 1249, Castaman, G., 0091, 0092, 0881 Castellini, C., 1274 Castello, A., 0429, 0716 Castro, E.B., 0776, 0783, 0786, 0789, 1171 Castro, F.A., 0528, 0963 Castro, I., 0664 Castro, J., 0123 Castro-Rios, M., 0307 Catalano, A., 0589 Catalano, G., 0031 Catalano, L., 0401 Catalano, R., 0044, 0156, 0198, 0199, 0636, 0665 Cataldi, I., 1182 Catana, A., 1423, 1424, 1493 Catania, G., 0049, 0508, 0663 Catarini, M., 0674, 1154 Catherwood, M.A., 0101, 0519, 1037, 1307, 1308 Cattaneo, C., 0285, 0608 Cattaneo, M., 0343 Caulder, E., 0324 Cauwelier, B., 0442 Cavalcanti, S., 0675 Cavalieri, E., 0178, 0284 Cavalli, F., 0418, 0863 Cavallin, M., 0460 Cavallo, F., 0422, 0693, 0695, 0883 Cavazzini, F., 0107 Cavé, H., 0367 Cavenagh, J., 0495, 0627 Cavet, J., 0211 Cavigliano, P.M., 0224, 0626 Cavo, M., 0401, 0696 Cayuela, J.M., 0060, 0373, 0383, 0397, 0553, 0958 Cazin, B., 0362 Cazzaniga, G., 0877, 0892 Cazzola, M., 0219, 0227, 0229, 0429, 0647, 0649 Ceausu, M., 1521 Cebula, B., 0112, 0276, 0520 Ceccolini, M., 0696 Cecere, F., 1226 Cedrone, M., 0991 Ceglarek, B., 0120 Cehiz Sagir, F., 1172 Cejkova, S., 0098, 0105 Cellini, A., 1182 Cemerikic, V., 0683, 1069, 1104 Cena, S., 0193 Ceran, F., 1522 Ceresa, E., 0418 Cerezuela, P., 1448 Cerezuela Martinez, P., 1269 Cermak, J., 0131, 0965, 0968, 0994, 1010 Cermakova, Z., 0257 Cermanova, M., 1210 Cerno, M., 0458 Cerny, A., 1339 Cerretti, R., 1381 Cerri, M., 0250, 0289 Cerutti, F., 0825 Cervantes, F., 0662 Cerveira, N., 0471 Cervera, J., 1063 Cervera, M., 1348, 1473, 1510 Cesaro, S., 1024 Cetin, M., 1055, 1469, 1472 Cetkovsky, P., 0965, 0994 Cevreska, L., 1373, 1410, 1540 Chabannon, C., 0158, 0455 Chachaj, A., 1288 Chachaty, E., 0617 Chae, M.J., 1337 Chaiba, L., 1134 Chaibi, P., 0923
Chaidos, A., 0456, 0498, 0599, 0686 Chakraverty, R., 1014 Chaligné, R., 0413, 0443 Chameisi, Z., 1444 Chamone, D.A.F., 0526, 1233 Champlin, R., 0500 Chan, A., 0502 Chan, A.K., 0339 Chan, N.P., 0502, 1030 Chanalaris, A., 0544, 1014 Chancharunee, S., 1117 Chandrinou, H., 0993 Chang, P.Y., 1403 Chang, S-H., 1518 Chang, Y.H., 1337 Chang, Y.T, 0566 Chantepie, S., 1108 Chao, T.Y., 1403 Chapiro, E., 0887 Chaplin, T., 0172, 0627 Chapman, C, 0679 Chapuis, N., 0040, 0323 Charafeddine, K., 1355 Charafeddine, M., 1174, 1355 Charbonnier, A., 0359, 0485, 0490, 0859, 1047 Charlinski, G., 0120, 0263 Charlot, C., 0908, 0980 Charron, D., 0192 Charrow, J., 0734 Chase, A., 0551 Chasiotis, D., 0179 Chassevent, A., 1011 Chatal, J.-F., 0409 Chatziangelidou, C., 0657 Chatziantoniou, V., 1022 Chatzikyriakidou, A., 1551 Chatzileonida, E., 1186 Chatzopoulou, D., 0983 Chaudhary, A., 1492 Chauhan, D., 0269, 0689 Chaury, M.P., 0428 Chelgoum, Y., 0454 Chelysheva, E.Yu., 1016, 1362, 1365 Chen, C.-L., 0030 Chen, C.-Y., 0030, 0606, 0610 Chen, C.Y., 0207, 0228 Chen, H., 0450 Chen, J., 0417, 0511 Chen, L., 0377 Chen, P.Y., 0610 Chen, T.S., 1403 Chen, Y.-C., 0030 Chen, Y.-H., 0450 Chen, Y., 0450 Chen, Y., 0386 Chen, Y.C., 1403 Chen, Y.C., 0207, 0606 Chen, Y.C., 0207, 0228 Chen, Y.K., 0207 Chena, C., 0103 Cheng, C.K., 1030 Cheng, G., 0390, 0502, 1030 Cheng, K., 0935 Cheng, K.C.K., 0935 Cheng, S.H., 0935 Cheon, G.J., 0300, 1337 Cheong, J.W., 0996, 1251, 1254 Cherenkevich, S.N., 1431 Cherif, H., 0061 Chermat, F., 0428 Chern, J., 1518 Chernykh, Y., 1496 Cherry, A.M., 0381 Chertkov, L., 0970 Cheung, A.P.L., 0935 Chevret, S., 0048 Cheze, S., 0222, 0427, 1108 Chhanabhai, M., 1470 Chiappella, A., 0408 Chiarelli, L.R., 0784 Chiarenza, A., 0261, 0665 Chiaretti, S., 0013, 0747 Chiari, E., 0145 Chiarvesio, A., 0460 Chiavarina, B., 0389 Chiecchio, L., 0886 Chierichini, A., 0991 Chigrinova, E., 1246 Child, J.A., 0274 Chillón, M.C., 0174, 0699, 0700 Chilosi, M., 1060 Chistolini, A., 0825 Chiu, C.F., 0143, 1051 Chiusolo, P., 0589, 0676, 0823, 0990, 1008, 1078 Cho, B.-S., 0939, 0941, 0961, 1407 Cho, G.J., 1240 Cho, S.-G., 0939, 0941, 0961, 1407 Cho, S.H., 0256, 1119 Cho, Y.H., 0719 Choi, C.W., 0300, 1337 Choi, I.-H., 0190 Choi, J.H., 0056 Choi, Y., 0940 Choi, Y.J., 1240 Chomel, J.C., 1017 Chomienne, C., 0192 Chomyn, V., 1322 Chott, A., 0701, 0711, 0864, 1188 Chou, W.-C., 0030, 0207, 0606, 0610 Choudhury, A., 0094 Choumerianou, D., 0012 Chowdhury, M., 1541 Choy, G.S., 1470 Christakis, J., 0778 Christie, D.R.H., 0717 Christoforidis, A., 0803 Christopoulos, Ch.N., 1543 Christopoulou, M., 0657 Christopoulou Cokk, V., 1380 Christoulas, D., 0885, 0914 Chriva-Internati, M., 0505, 1220 Chromcak, F., 0774 Chu, P., 0911 Chui, C.H., 0502 Chukavina, M., 1496 Chumak, A., 1101, 1344 Chumchalova, J., 0098, 0451, 1110 Chung, I.J., 0256, 1119 Chung, J.S., 0253, 1240 Chybicka, A., 0071, 0585 Ciaffi, P., 0849 Ciancia, R., 0650 Ciccone, G., 0408 Ciceri, F., 0196, 1085 Cil, T., 0637, 0937, 1219, 1402, 1404 Cilloni, D., 0006, 0044, 0156, 0198, 0199, 0569, 0636, 0665 Cimolin, L., 0193 12 th Congress of the European Hematology Association Cimponeriu, D., 1232 Cioch, M., 1107, 1349, 1536 Ciolli, S., 0259, 0260 Cipolla, A., 0824, 0826, 1159 Cipolleschi, M.G., 1446 Cipressi, S., 1453 Cirstea, D., 0312 Cisleanu, D., 1468 Cisneros, J.M., 1269 Ciufu, C., 1398, 1468 Ciuleanu, T., 0377 Civallero, M., 0692 Civriz, S., 1353 Civriz Bozdag, S., 1353 Clappier, E., 0383 Clark, A.D., 1248 Clark, M., 0454 Clark, R.E., 0532 Claus, R., 0233 Claussen, U., 0129 Clavert, A., 0540 Clavio, M., 0049, 0177, 0468, 1538 Cleeland, C., 0772 Clement, L., 0464 Clerici, D., 1085 Cleto, E., 0783, 0786 Clode, N., 0434 Cloos, J., 0478, 0481 Cmejla, R., 1123 Cmunt, E., 0114 Cobos, E., 0505, 1220 Cocorocchio, E., 1057 Coelho, P.S., 1038 Cognetti, F., 0747 Cohen, R., 0742 Cohen, Y., 0655, 0893, 1435 Coiffier, B., 0292, 0407 Coiteux, V., 0222, 0272, 0273, 0427, 0690 Colapietro, P., 1350 Colarossi, S., 0006, 0536, 0569, 1060 Colassantti, M.D., 0528 Colavita, I., 1135 Cole, A., 0348 Cole, D.S., 0065 Coletti, V., 0750, 1195 Colita, A., 0662 Colla, C., 0884 Collins, P.W., 0834 Collinson, P.O., 0066 Colman, S., 0007 Colnaghi, F., 0367, 0670 Colombat, P., 0115, 0362 Colombi, M., 0623 Colombo, A., 0670 Colombo, N., 1538 Colomer, D., 0487 Colomo, L., 0706 Colorado, M., 0712, 1279 Colovic, M., 0753, 1104, 1515 Colunga, C., 1046 Coman, M., 1521 Combs, A., 0324 Comincini, S., 0218 Comitini, G., 0650 Conchillo, A., 0097 Conconi, A., 0250, 0863, 1088 Conde, E., 0303 Coneska-Jovanova, B., 1150 Congiu, A.G., 0508, 0663 Conran, N., 0916 haematologica/the hematology journal | 2007; 92(s1) | g
Page 1 and 2:
haematologica the hematology journa
Page 3 and 4:
Information for readers, authors an
Page 5 and 6:
EHA Executive Board E. Hellström-L
Page 7 and 8:
Poster session I POSTER SESSION POS
Page 9 and 10:
12 th Congress of the European Hema
Page 11 and 12:
dasatinib. Methods. We studied Ikar
Page 13 and 14:
Expression of the oncogene H-Ras an
Page 15 and 16:
is the gene for the erythropoietin
Page 17 and 18:
safety of a slow-release liposomal
Page 19 and 20:
0029 OUTCOME OF THE TREATMENT OF AD
Page 21 and 22:
drug-induced apoptotic response of
Page 23 and 24:
41% in the PI3K- group (p=0.001). I
Page 25 and 26:
Acute myeloid leukemia - Clinical I
Page 27 and 28:
to 60 years (n=116, or 72%) receive
Page 29 and 30:
0056 PROGNOSTIC SIGNIFICANCE OF FLT
Page 31 and 32:
Anemia and Bone marrow failure 0061
Page 33 and 34:
tified with the current protocol. S
Page 35 and 36:
new cases of lead poisoning due to
Page 37 and 38:
icance, from baseline to week 6 (p
Page 39 and 40:
0086 THROMBELASTOGRAPHIC CHART RELI
Page 41 and 42:
trials. The aim of this retrospecti
Page 43 and 44:
tant function in this disease, nega
Page 45 and 46:
ed to a favorable outcome. Bialleli
Page 47 and 48:
stronger levels of p21 in the cell
Page 49 and 50:
hematological centers in one countr
Page 51 and 52:
ure 1). Conclusions. Results for re
Page 53 and 54:
patients. After a median follow-up
Page 55 and 56:
Cytogenetics and Molecular diagnost
Page 57 and 58:
0135 ROUTINE DETECTION OF CYTOGENET
Page 59 and 60:
(MMolR, defined as a BCR-ABL x 100
Page 61 and 62:
0146 ARSENIC TRIOXIDE INDUCES ACCUM
Page 63 and 64:
tinguish between genotypic B-cell l
Page 65 and 66:
Genomics and proteomics 0158 PLASMA
Page 67 and 68:
0164 EVALUATION OF MULTIPLEX LIGATI
Page 69 and 70:
each patient’s replicate conditio
Page 71 and 72:
0174 RELATION BETWEEN LOW PML-RARα
Page 73 and 74:
0179 ESHAP VS GIN AS SALVAGE AND MO
Page 75 and 76:
Immunology and gene therapy 0184 EA
Page 77 and 78:
Cell viability was not affected by
Page 79 and 80:
month is not relevant to chronic Gv
Page 81 and 82:
Infection and supportive care I 020
Page 83 and 84:
0206 POTENTIAL ROLE OF CMV IN THE O
Page 85 and 86:
3H-thymidine uptake in cell culture
Page 87 and 88:
0217 TUBERCULOSIS AMONG A COHORT OF
Page 89 and 90:
0222 COMPARISON OF IWG 2006 AND IWG
Page 91 and 92:
tem (IPSS) to h-MDS was also invest
Page 93 and 94:
PCH97-19) were studied. Conventiona
Page 95 and 96:
of erythroid colonies was reduced i
Page 97 and 98:
0245 POTENT AND SELECTIVE INHIBITIO
Page 99 and 100:
0250 INACTIVATION OF SUPPRESSOR OF
Page 101 and 102:
Bortezomib 1.3 mg/m 2 days 1,4,8,11
Page 103 and 104:
Response was defined according to E
Page 105 and 106:
G-CSF can be used in neutropenic pa
Page 107 and 108:
ence and functional activity of CD8
Page 109 and 110:
itating tumor development, or engag
Page 111 and 112:
phoma and SNT-13, -15 were establis
Page 113 and 114:
usage (2/20 ie 10%) were observed.
Page 115 and 116:
0294 MYCOSIS FUNGOIDES. IMMUNOHYSTO
Page 117 and 118:
(range, 1-6) and 11 treatment cycle
Page 119 and 120:
0306 RISK-ADAPTED IMMUNOCHEMOTHERAP
Page 121 and 122:
functional activity was confirmed b
Page 123 and 124:
No major toxicity, neither hematolo
Page 125 and 126:
enewal potential of X-RAR-positive
Page 127 and 128:
(50-99) respectively. Serial analys
Page 129 and 130:
cell-interaction, adhesion and acti
Page 131 and 132:
0340 ALTERED FIBRIN CLOT STRUCTURE
Page 133 and 134:
Conclusions. This study demonstrate
Page 135 and 136:
0354 FACTOR V LEIDEN HOMOZYGOUS GEN
Page 137 and 138:
Results. From July 2005 through Mar
Page 139 and 140:
0364 CLINICAL EFFICACY OF OXALIPLAT
Page 141 and 142:
one marrow and peripheral blood ste
Page 143 and 144:
ecently suggested (Boissel et al.,
Page 145 and 146:
0378 SAFETY AND EFFICACY OF THE TER
Page 147 and 148:
Cytogenetics and molecular diagnost
Page 149 and 150:
0385 CYTOPLASMIC MUTATED NUCLEOPHOS
Page 151 and 152:
0390 ELTROMBOPAG RAISES PLATELET CO
Page 153 and 154:
factor for the achievement of CR wa
Page 155 and 156:
The cases of RAS showed two peaks o
Page 157 and 158:
is 85%. Seven out of the 25 relapse
Page 159 and 160:
0409 FRACTIONATED RADIOIMMUNOTHERAP
Page 161 and 162:
0414 COMPARATIVE ANALYSIS OF THE CO
Page 163 and 164:
successfully managed with GM-CSF di
Page 165 and 166:
49% for PCR positive patients (95%
Page 167 and 168:
+8 (1 PR+1 HI) and 14/24 pts with c
Page 169 and 170:
(e.g. bcr-abl leading to CML). CSC
Page 171 and 172:
0438 TERC MUTATIONS ANALYSIS IN PAT
Page 173 and 174:
observed in all mice. Analysis of l
Page 175 and 176:
ex-vivo expansion of HUCB-derived H
Page 177 and 178:
ic kidney disease in univariate or
Page 179 and 180:
One hundred eleven CN AML patients,
Page 181 and 182:
to asses intestinal epithelial dama
Page 183 and 184:
genesis of acute myeloid leukaemia
Page 185 and 186:
polymorphism at nucleotide 4889 of
Page 187 and 188:
expression along with a decreased C
Page 189 and 190:
0487 MUTATIONAL STATUS OF NUCLEOPHO
Page 191 and 192:
previously reported, a single cours
Page 193 and 194:
0497 SINGLE AGENT CLORETAZINE (VNP4
Page 195 and 196:
ly received melphalan-based chemoth
Page 197 and 198:
were similar among the 3 groups. Ho
Page 199 and 200:
Methods. Several read-out systems w
Page 201 and 202:
0518 SERUM AND CELLULAR EXPRESSION
Page 203 and 204:
0523 DNA REPAIR INHIBITION IN RESTO
Page 205 and 206:
held true when BMI-1 expression was
Page 207 and 208:
Ph + cells in the bone marrow). We
Page 209 and 210:
derivative chromosome (4p16, 7p14,
Page 211 and 212:
0545 STABILIZED BONE MARROW IS NOT
Page 213 and 214:
obtained in low (Sokal) risk patien
Page 215 and 216:
median dose intensity being 800 (21
Page 217 and 218:
from pivotal clinical trials. Metho
Page 219 and 220:
Cytogenetics and Molecular diagnost
Page 221 and 222:
to set up and optimize a D-HPLC-bas
Page 223 and 224:
0576 WESTERN BLOT IDENTIFICATION OF
Page 225 and 226:
Basic disease was AML (n=5), ALL (n
Page 227 and 228:
0588 EXTRACORPOREAL PHOTOPHORESIS F
Page 229 and 230:
acquire a cytolytic capacity agains
Page 231 and 232:
informed vignettes describing healt
Page 233 and 234:
using CHOP-21 in the UK, pegfilgras
Page 235 and 236:
0609 SOFT TISSUE COMPLICATIONS IN P
Page 237 and 238:
inding lectin (MBL) gene by polymer
Page 239 and 240:
all infection rate (p=0.12) as well
Page 241 and 242:
Myelodysplastic syndromes II 0623 M
Page 243 and 244:
formation (in total 28 samples). Ti
Page 245 and 246:
sion. In addition, confocal analysi
Page 247 and 248:
Myeloproliferative disorders - Clin
Page 249 and 250:
open-label, multi-centre study enro
Page 251 and 252:
iopsies after 6 and 12 months treat
Page 253 and 254:
Myeloproliferative disorders Chroni
Page 255 and 256:
ash, muscolar cramps, diarrhoea, he
Page 257 and 258:
induced significant apoptosis (mean
Page 259 and 260:
Myeloma and other monoclonal gammop
Page 261 and 262:
the therapy of choice for POEMS is
Page 263 and 264:
er patient does not indicate such t
Page 265 and 266:
Myeloma and other monoclonal gammop
Page 267 and 268:
secutive patients with MM, referred
Page 269 and 270:
whether gene expression values may
Page 271 and 272:
0705 THE SHIFT OF TREATMENT FOR NAS
Page 273 and 274:
0710 CLINICO-PATHOLOGICAL FEATURES,
Page 275 and 276:
patients presented a stage IV disea
Page 277 and 278:
plete remission or recurrent diseas
Page 279 and 280:
known at NHL diagnosis, were includ
Page 281 and 282:
0731 THE IMPACT OF HIV ON NON-HODGK
Page 283 and 284:
patients had died of their underlyi
Page 285 and 286:
scripts and proteins most affected
Page 287 and 288:
modulated after 24 h (37 up- and 59
Page 289 and 290:
0753 A SUSTAINED REMISSION OF IDIOP
Page 291 and 292:
and treatment, has rarely been syst
Page 293 and 294:
uncontrolled massive bleeding affec
Page 295 and 296:
Results. A total of 396 patients we
Page 297 and 298:
C30 questionnaire, and the correspo
Page 299 and 300:
wave length of light of reflected r
Page 301 and 302:
0783 PREVALENCE OF MEMBRANE PROTEIN
Page 303 and 304:
erozygous mother has a more severe
Page 305 and 306:
0794 CARDIAC MANIFESTATIONS IN A BR
Page 307 and 308:
0799 INEFFECTIVE ERYTHROPOIESIS IN
Page 309 and 310:
p=0.014 and p=0.003, respectively).
Page 311 and 312:
0809 CURRENT APPROACH TO CHELATION
Page 313 and 314:
Thrombosis II 0814 UNSUSPECTED PULM
Page 315 and 316:
the 97.5th percentile (5.2 U/mL) ge
Page 317 and 318:
symptoms of DVT, 3 (7.89%) previous
Page 319 and 320:
Transfusion medicine and vascular b
Page 321 and 322:
tions (most bacterial, 2 malaria, 6
Page 323 and 324:
0844 INCREASED LEUKOCYTE-PLATELET I
Page 325 and 326:
0851 CORD BLOOD DERIVED MESENCHYMAL
Page 327 and 328:
SIMULTANEOUS SESSION II Chronic mye
Page 329 and 330:
0862 COMPARISON OF DASATINIB TO HIG
Page 331 and 332:
0867 COMPREHENSIVE GERIATRIC ASSESS
Page 333 and 334:
0872 MN1 INDUCES LEUKEMIA IN MICE A
Page 335 and 336:
0877 PAX5/TEL TRANSDUCED PRE-BI CEL
Page 337 and 338:
0882 CISPLATIN INDUCES THROMBIN GEN
Page 339 and 340:
have an early manifestation of typi
Page 341 and 342:
0892 INTEGRATION OF GENOME WIDE SNP
Page 343 and 344:
0897 THE PHENOTYPE OF JAK2V617F MUT
Page 345 and 346:
gest diverse sequences of NPM mutan
Page 347 and 348:
2004 to January, 2006. At enrollmen
Page 349 and 350:
with a p value of ≥ 0.10. Sets of
Page 351 and 352:
BRIC 126 and 4N1K) in cells lacking
Page 353 and 354:
sclerosis[NS] and 12 Mixed cellular
Page 355 and 356:
0927 MK-0457, A NOVEL MULTIKINASE I
Page 357 and 358:
Publication Only 0933 CLINICAL FEAT
Page 359 and 360:
HSCT from the available Asian as we
Page 361 and 362:
that the incidence of JAK2 mutation
Page 363 and 364:
without type 2 diabetes. Methods. T
Page 365 and 366:
pts (38.8%) that were isolated (abs
Page 367 and 368:
y using the Miltenyi CD34 isolation
Page 369 and 370:
0969 COMPARISON OF CD25 IMMUNOHISTO
Page 371 and 372:
cytes was 24 days (range 8-32 days)
Page 373 and 374:
a cytogenetic hallmark for M4/M5 su
Page 375 and 376:
normal human BM B progenitor cells
Page 377 and 378:
0994 INCIDENCE OF INVASIVE ASPERGIL
Page 379 and 380:
3 of disease relapse.TRM at day+100
Page 381 and 382:
survival of five years. This dismal
Page 383 and 384:
1011 FLOW CYTOMETRIC DNA INDEX AND
Page 385 and 386:
1018 THE EFFECT OF THE SUGARBAKER P
Page 387 and 388:
1024 KIR/HLA CLASS I MISMATCHING AN
Page 389 and 390:
ment details and thrombotic histori
Page 391 and 392:
1036 INCIDENCE AND SPECTRUM OF INFE
Page 393 and 394:
tinely by our stem cell lab prior t
Page 395 and 396:
tion to a translocation t(5;14)(q35
Page 397 and 398:
ment of CML and induces a high rate
Page 399 and 400:
due to reactivation and/or progress
Page 401 and 402:
1063 ABNORMAL METHYLATION STATUS OF
Page 403 and 404:
1069 CLINICAL RELEVANCE OF REGULATO
Page 405 and 406:
1076 SERUM LEVELS OF SOLUBLE HLA CL
Page 407 and 408:
patient is still undergoing intensi
Page 409 and 410:
nificant MVD differences were detec
Page 411 and 412:
dictor of OS (p=0.004). High dose t
Page 413 and 414:
1099 ALTERATIONS IN THE NATURAL KIL
Page 415 and 416:
1105 CYTOGENETIC ABNORMALITIES IN 3
Page 417 and 418:
1110 CONSTITUTIVE ACTIVATION OF STA
Page 419 and 420:
efficacy results with a well-tolera
Page 421 and 422:
unmutated VH genes, and high and lo
Page 423 and 424:
Aims. Aim of this study was to pred
Page 425 and 426:
tested across a wide range of human
Page 427 and 428:
were incidentally diagnosed (52%).
Page 429 and 430:
ß2GP1 may be considered as determi
Page 431 and 432:
characterized in 198 β thalassaemi
Page 433 and 434:
1155 PLATELET AGGREGATION IN CHILDR
Page 435 and 436:
to-pelvic or perineal trauma. No me
Page 437 and 438:
in age. High prevalence of LBM amon
Page 439 and 440:
ecause some of the patients were or
Page 441 and 442:
of the drug is crucial to allow lon
Page 443 and 444:
egarding cost analysis of ASCT in G
Page 445 and 446:
ID Allo-BMT, 1 family one mismatche
Page 447 and 448:
admitted to ICU were discharged des
Page 449 and 450:
events -Postoperative states: 9,19%
Page 451 and 452:
efficacy and decreased atherosclero
Page 453 and 454:
1217 INCIDENCE OF EARLY STAGE IDIOP
Page 455 and 456:
1691GA and 1 homozygous 1691AA. The
Page 457 and 458:
1230 ASSOCIATION OF HEPARANASE GENE
Page 459 and 460:
posed, was: DF = (CD43%+FMC7%+CD79b
Page 461 and 462:
treatment of acute promyelocityc le
Page 463 and 464:
loaded group and 35 (70%) were non-
Page 465 and 466:
mild. Fas and soluble Fas ligand le
Page 467 and 468:
1265 POSACONAZOLE THERAPY IN REFRAC
Page 469 and 470:
ly express the cytoplasmic (inactiv
Page 471 and 472:
findings confirmed the significant
Page 473 and 474:
a less favorable prognosis. Interes
Page 475 and 476:
disease (HD), 4 patients (9%) with
Page 477 and 478:
1295 HEMOPHAGOCYTIC LYMPHOHYSTIOCYT
Page 479 and 480:
phamide 750 mg/m 2 on day 1, vincri
Page 481 and 482:
nomenon is unclear. It has been sug
Page 483 and 484:
oped mild thrombocytopenia (platele
Page 485 and 486:
gle dose of 54mg/m 2 rituximab furt
Page 487 and 488:
patients (pts), 36 male, with acute
Page 489 and 490:
esulting alterations of the endothe
Page 491 and 492:
(range 1-7) and 28,6% of patients h
Page 493 and 494:
three decades. In vivo, Ara-C is tr
Page 495 and 496:
statistical analysis. Results. Seve
Page 497 and 498:
Results. Though there was no recogn
Page 499 and 500:
2% and 19% of patients with or with
Page 501 and 502:
were older than 65 y) which can be
Page 503 and 504:
1376 RESVERATROL INDUCED P53 MEDIAT
Page 505 and 506:
median time of 21 days to reach >0.
Page 507 and 508:
ly. Conclusions. 1. Combined intens
Page 509 and 510:
to the presence of IVS1-6 mutation
Page 511 and 512: fy predictive factors for these abn
Page 513 and 514: acute leukemia. However, we cannot
Page 515 and 516: agents. They involve primarily the
Page 517 and 518: voriconazole for 2 months followed
Page 519 and 520: typed using a commercially availabl
Page 521 and 522: low up of ABL KD mutations’ level
Page 523 and 524: with development of BC/AP. 2. EVI-1
Page 525 and 526: 1447 THE IMPACT OF DISPARITY IN SHO
Page 527 and 528: three had visual field defects, two
Page 529 and 530: acquired mutation most prone to cau
Page 531 and 532: 1466 ROS GENERATION AND APOPTOSIS I
Page 533 and 534: 1473 DIARRHEIC SYNDROME, A CLINICAL
Page 535 and 536: gene fusion is an independent progn
Page 537 and 538: 1484 EPIDEMIOLOGY AND RESPONSE TO T
Page 539 and 540: 1492 FREQUENCY OF MEDITERRANEAN GLU
Page 541 and 542: immune globulin was administered at
Page 543 and 544: maintained on Imatinib 400 mg. Afte
Page 545 and 546: Hodgkin’s disease is well known,
Page 547 and 548: gram provided a unique chance to de
Page 549 and 550: even when ADP-induced plt activatio
Page 551 and 552: medullary involvement of multiple m
Page 553 and 554: 1540 ADMINISTRATION OF G-CSF AND CH
Page 555 and 556: 1548 QUALITY ANALYSIS OF THE MULTID
Page 557 and 558: Index of authors A Aapro, M., 0377,
Page 559 and 560: Bahr, J., 0148 Bai, M., 1551 Baia,
Page 561: Bottini, P.V., 1181 Botto, B., 0408
Page 565 and 566: De Keersmaecker, K., 0442, 0875 De
Page 567 and 568: El-Sharkawy, N., 0016 Elwahidi, G.,
Page 569 and 570: Garcia-Frade, J., 0346, 0680, 1105
Page 571 and 572: H Haas, N., 0742 Haas, O.A., 0001,
Page 573 and 574: Jaksic, B., 0127, 0446 Jaksic, O.,
Page 575 and 576: Körmöczi, G., 0848 Kornblau, S.,
Page 577 and 578: Lin, L.-I., 0030, 0484 Lin, T., 012
Page 579 and 580: Massé, A., 0249 Massó, P., 1287,
Page 581 and 582: Musto, P., 0254, 0401, 0422, 0569,
Page 583 and 584: Papadavid, E., 1442 Papageorgiou, E
Page 585 and 586: Probatova, N., 0704 Prochazka, V.,
Page 587 and 588: Rykavicin, O., 0504 Ryningen, A., 0
Page 589 and 590: Sirard, C., 0127, 0128 Sirigou, A.,
Page 591 and 592: Thiebaut, A., 0454 Thieblemont, C.,
Page 593 and 594: Vincenzi, C., 1060 Viniou, N.-A., 0
Page 595 and 596: Zouabi, H., 0503, 0999 Zoumbos, N.C
Page 597 and 598: 12 th Congress of the European Hema
Page 603: 12 th Congress of the European Hema
show all

12th Congress of the European Hematology ... - Haematologica

Create successful ePaper yourself

Delete template?

Save as template?